ProMeris

RSS

Withdrawn

This medicine's authorisation has been withdrawn

metaflumizone
MedicineVeterinaryWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.

български (BG) (217.29 KB - PDF)

Amharc

español (ES) (192.56 KB - PDF)

Amharc

čeština (CS) (217.67 KB - PDF)

Amharc

dansk (DA) (191.94 KB - PDF)

Amharc

Deutsch (DE) (193.36 KB - PDF)

Amharc

eesti (ET) (191.37 KB - PDF)

Amharc

ελληνικά (EL) (219.08 KB - PDF)

Amharc

français (FR) (193.21 KB - PDF)

Amharc

italiano (IT) (191.59 KB - PDF)

Amharc

latviešu (LV) (213.28 KB - PDF)

Amharc

lietuvių (LT) (214.74 KB - PDF)

Amharc

magyar (HU) (212.15 KB - PDF)

Amharc

Malti (MT) (218.75 KB - PDF)

Amharc

Nederlands (NL) (191.68 KB - PDF)

Amharc

polski (PL) (216.46 KB - PDF)

Amharc

português (PT) (192.4 KB - PDF)

Amharc

română (RO) (214.2 KB - PDF)

Amharc

slovenčina (SK) (215.86 KB - PDF)

Amharc

slovenščina (SL) (208.53 KB - PDF)

Amharc

suomi (FI) (191.92 KB - PDF)

Amharc

svenska (SV) (191.72 KB - PDF)

Amharc

Product information

български (BG) (389.52 KB - PDF)

Amharc

español (ES) (328.73 KB - PDF)

Amharc

čeština (CS) (374.1 KB - PDF)

Amharc

dansk (DA) (330.12 KB - PDF)

Amharc

Deutsch (DE) (340.98 KB - PDF)

Amharc

eesti (ET) (336.16 KB - PDF)

Amharc

ελληνικά (EL) (400.6 KB - PDF)

Amharc

français (FR) (342.69 KB - PDF)

Amharc

italiano (IT) (310.69 KB - PDF)

Amharc

latviešu (LV) (368.86 KB - PDF)

Amharc

lietuvių (LT) (376.46 KB - PDF)

Amharc

magyar (HU) (368.57 KB - PDF)

Amharc

Malti (MT) (376.05 KB - PDF)

Amharc

Nederlands (NL) (331.24 KB - PDF)

Amharc

polski (PL) (391.6 KB - PDF)

Amharc

português (PT) (331.45 KB - PDF)

Amharc

română (RO) (368.38 KB - PDF)

Amharc

slovenčina (SK) (386.11 KB - PDF)

Amharc

slovenščina (SL) (371.43 KB - PDF)

Amharc

suomi (FI) (337.57 KB - PDF)

Amharc

svenska (SV) (330.13 KB - PDF)

Amharc

Íslenska (IS) (332.3 KB - PDF)

Amharc

norsk (NO) (340.4 KB - PDF)

Amharc
Latest procedure affecting product information:IB/0012
08/07/2015

български (BG) (190.37 KB - PDF)

Amharc

español (ES) (144.19 KB - PDF)

Amharc

čeština (CS) (184.81 KB - PDF)

Amharc

dansk (DA) (144.38 KB - PDF)

Amharc

Deutsch (DE) (146.91 KB - PDF)

Amharc

eesti (ET) (144.06 KB - PDF)

Amharc

ελληνικά (EL) (186.84 KB - PDF)

Amharc

français (FR) (141.5 KB - PDF)

Amharc

italiano (IT) (144.6 KB - PDF)

Amharc

latviešu (LV) (189.21 KB - PDF)

Amharc

lietuvių (LT) (179.82 KB - PDF)

Amharc

magyar (HU) (175.56 KB - PDF)

Amharc

Malti (MT) (198.96 KB - PDF)

Amharc

Nederlands (NL) (141.54 KB - PDF)

Amharc

polski (PL) (163.63 KB - PDF)

Amharc

português (PT) (144.35 KB - PDF)

Amharc

română (RO) (142.48 KB - PDF)

Amharc

slovenčina (SK) (181.1 KB - PDF)

Amharc

slovenščina (SL) (174.66 KB - PDF)

Amharc

suomi (FI) (144.95 KB - PDF)

Amharc

svenska (SV) (141.76 KB - PDF)

Amharc

Íslenska (IS) (141.82 KB - PDF)

Amharc

norsk (NO) (141.71 KB - PDF)

Amharc

Product details

Name of medicine
ProMeris
Active substance
metaflumizone
International non-proprietary name (INN) or common name
metaflumizone
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QP53AX25

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Authorisation details

EMA product number
EMEA/V/C/000107
Marketing authorisation holder
Pfizer Limited 

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom

Marketing authorisation issued
19/12/2006
Revision
8

Assessment history

This page was last updated on

Share this page